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Cholesterol is pumped out of the cells in different tissues,
including the vasculature, intestine, liver, and kidney, by the
ATP-binding cassette transporters. Ligands that activate
the liver X receptor (LXR) modulate this efflux. Here we
determined the effects of LXR agonists on the regulation of
phosphate transporters. Phosphate homeostasis is regulated
by the coordinated action of the intestinal and renal
sodium–phosphate (NaPi) transporters, and the loss of this
regulation causes hyperphosphatemia. Mice treated with
DMHCA or TO901317, two LXR agonists that prevent
atherosclerosis in ApoE or LDLR knockout mice, significantly
decreased the activity of intestinal and kidney proximal
tubular brush border membrane sodium gradient-dependent
phosphate uptake, decreased serum phosphate, and
increased urine phosphate excretion. The effects of DMHCA
were due to a significant decrease in the abundance of the
intestinal and renal NaPi transport proteins. The same effect
was also found in opossum kidney cells in culture after
treatment with either agonist. There was increased nuclear
expression of the endogenous LXR receptor, a reduction in
NaPi4 protein abundance (the main type II NaPi transporter
in the opossum cells), and a reduction in NaPi co-transport
activity. Thus, LXR agonists modulate intestinal and renal
NaPi transporters and, in turn, serum phosphate levels.
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Increase in serum inorganic phosphate (Pi) concentration
(hyperphosphatemia) is associated with endothelial dysfunc-
tion1 and increased incidence of cardiovascular disease,2
including accelerated atherosclerosis,3 vascular stiffness,4 and
vascular calcification.2,5–7 We have recently found that
hyperphosphatemia in vivo and increase in extracellular Pi
in vascular smooth muscle cells grown in cell culture induce
lipid accumulation and vascular calcification, further
emphasizing a role for Pi in vascular disease.8 Serum Pi
concentration is determined by coordinated activity of the
renal and intestinal sodium-gradient-dependent Pi (Na-Pi)
transporters.9–11 In the renal proximal tubule, at least three
different phosphate transporters are expressed in the brush
border membrane: type II NaPi-2a and NaPi-2c, and type III
PiT-2.12,13 Interestingly, both type III NaPi transporters, PiT-
1 and PiT-2, are expressed in mouse ileum; however, a third
type II NaPi transporter (NaPi-2b) is considered to be the
main transporter that mediates phosphate absorption in the
gut.14,15 Novel pathways that can inhibit renal and intestinal
Na-Pi transporters and prevent hyperphosphatemia, espe-
cially in the presence of chronic kidney disease, are likely to
have important effects in the inhibition of hyperpho-
sphatemia-mediated cardiovascular disease.
The nuclear receptors are involved in the regulation of
essential metabolic functions, including glucose and lipid
metabolism, reverse cholesterol transport, and inflamma-
tion.16–18 All of these factors have an important role in the
development of cardiovascular disease. Activation of liver X
receptor (LXR), a nuclear receptor, has been shown to
prevent the development of atherosclerosis in ApoE-knock-
out19 and low-density lipoprotein receptor-knockout20
mice.21,22 In addition, LXR activation reduces the expression
of several genes, iNOS, COX2, MMP9, IL-1b, and IL-6, which
are mediators of inflammation and atherosclerosis.23,24 LXR
is present in two different isoforms. LXRa (NR1H3) is mostly
expressed in liver, intestine, kidney, spleen, macrophages, and
adipose tissue. The second isoform LXRb (NR1H2) is
ubiquitously expressed.25 LXRs belong to a family of the
type II nuclear receptors, which form heterodimers with
the retinoid X receptor and, on ligand binding, stimulate
the expression of target genes.26,27 Recently, the oxidized
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cholesterol derivatives (oxysterols) have been identified as
their natural ligands for LXR.28 Oxysterols are formed in
amounts proportional to the cholesterol content in the cell;
therefore, LXRs operate as cholesterol sensors, which protect
from cholesterol overload by inhibiting intestinal cholesterol
absorption.19,29 LXRs stimulate cholesterol efflux from cells
via the activation of adenosine-triphosphate-binding cassette
(ABC) transporters for the subsequent transport of choles-
terol to the liver, conversion to bile acids, and biliary
excretion.27,30,31 However, some synthetic non-steroidal LXR
agonists (TO901317 and GW3965) have shown to induce
lipogenesis mainly through the activation of sterol-regula-
tory-element-binding protein 1c, a master regulator of lipids.
In contrast to this, our group22 and others32 have demonstrated
that a new steroidal LXR ligand, N,N-dimethyl-3b-hydroxy-
cholenamide (DMHCA), activates the ABC transporters that
mediate reverse cholesterol transport but does not activate
lipogenesis.
In addition to the liver and the intestine, LXRa and LXRb
are also highly expressed in the kidney.33,34 Although LXR
agonists have been shown to increase the activity of the
intestinal and renal ABC cholesterol transporters ABCA1 and
ABCG1,35,36 their potential effect in the modulation of
intestinal and renal Na-Pi transporters have not been studied.
In this study, we document a novel role for the LXR-
activating ligands, DMHCA and TO901317, in the inhibition
of the major renal and intestinal Na-Pi transporters, resulting
in a decrease of serum phosphate levels. This study along
with our previous findings of reduction of atherosclerosis,
suggests that LXR-activating ligands, such as DMHCA,
capable of inducing reverse cholesterol transport without
the lipogenic effects might be a promising therapeutic
agent in the prevention of hyperphosphatemia and its
cardiovascular consequences.
RESULTS
The effects of the LXR agonists on renal and intestinal
gene regulation
In our initial studies, we determined the effects of both
T0901317 and DMHCA on potential LXR targets in the
kidney and the intestine.22 We found that both T0901317 and
DMHCA increased ABCA1 and ABCG1 mRNA abundance in
the kidney and the ileum (Figure 1). As previously shown in
hepatocytes and macrophages,32 T0901317 also increased
sterol-regulatory-element-binding protein 1c, FAS, and
SCD-1 mRNA abundance in the kidney and the ileum;
however, the effects of DMHCA on sterol-regulatory-
element-binding protein 1c, FAS, and SCD-1 were minimal
(Figure 1). These results were also in agreement with the
previous data, showing the activation of LXR target genes in the
kidney when the mice were treated with TO901317.37
Upregulation of ABCA1 and stearoyl-CoA desaturase 1 protein
in kidney and ileum was also confirmed by western blotting and
immunofluorescence microscopy (Figure 1c–e). No significant
effects were observed in the expression of carbohydrate-
responsive-element-binding protein and liver pyruvate kinase.
Treatment with DMHCA or TO901317 causes decreases in
Naþ -dependent phosphate uptake in kidney and ileum
brush border membrane (BBM)
In kidney BBM, sodium-dependent Pi uptake was reduced by
20% and 15% in the DMHCA- and TO901317-treated mice,
respectively. Treatment with DMHCA had even more marked
effects in the ileum where sodium-dependent Pi uptake was
reduced by 56% and by 51% when mice were treated with
TO901317 (Figure 2). In all cases, sodium-gradient-indepen-
dent Pi transport was measured by using choline chloride
rather than sodium chloride. An average of 5% of total
uptake in the kidney BBM and an average of 14% of the total
uptake in the ileum BBM was due to Na-independent Pi
uptake, and this Na-independent component of total uptake
was modified by neither DMHCA nor TO901317. Therefore,
both drugs are inhibiting the transport of Pi in both epithelia.
The DMHCA- or TO901317-induced decrease in renal
and intestinal NaPi transport activity was paralleled by an
increase in urinary Pi excretion and a small but significant
decrease in serum Pi concentration (Figure 3). Changes in the
urinary glucose or protein excretion were not detectable
after treatment; however, a small significant decrease in the
urine pH was detected in the treated mice (Supplementary
Figure A online).
Treatment with DMHCA or TO901317 decreases serum
Pi and increases serum FGF23
To determine the serum levels of Pi, Ca, FGF23, and
parathyroid hormone, blood was collected when animals
were killed. Treatment with TO901317 caused a 20% decrease
in serum phosphate concentration, with a smaller reduction
of 14% after treatment with DMHCA (Figure 3a). This is
associated with an increase ofB30% in the urine phosphate
excretion with either compound (Figure 3b). No significant
changes in the serum calcium concentration were observed
(Figure 3c). Additionally treatment with TO901317 caused a
64% increase in serum FGF23 concentration, with a smaller
increase of 46% after treatment with DMHCA (Figure 4a).
No significant changes in the serum parathyroid hormone
levels were observed after treatment with either compound
(Figure 4b).
Treatment with DMHCA or TO901317 causes decreases in
NaPi cotransporter protein and mRNA abundance in
kidney and ileum
To determine the mechanism of the LXR-agonist-mediated
decrease in renal BBM NaPi cotransport activity, we
determined the abundance of BBM NaPi cotransporters by
western blotting. We found that treatment with DMHCA or
TO901317 caused significant decreases in the protein
abundance of all of the three renal transporters, namely,
NaPi-2a, NaPi-2c, and Pit-2 (Figure 5a). The effect of these
compounds on the renal NaPi transporter abundance was
independent of alterations in the protein abundance of the
PDZ-domain-interacting proteins, namely, NHERF-1 and
PDZK-1 (Figure 5c). These proteins are well known for the
regulation of the renal phosphate transporters. In addition,
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Figure 1 | Effect of the LXR agonist DMHCA and TO901317 on the abundance of LXR target genes in mouse kidney and ileum.
(a, b) LXR target gene mRNA abundance in kidney and ileum was analyzed by real-time quantitative PCR. TO901317 induced significant
increases in the mRNA abundance of ABCA1 and ABCG1 as well as SREBP1c, FAS, and SCD1. Increases in the mRNA abundance of these
genes with DMHCA were lower than activation by TO901317, especially activation of lipogenic genes, such as SREBP1c, FAS, and SCD1.
DMHCA or TO901317 did not activate ChREBP and LPK, neither in kidney nor in ileum. (c) ABCA1 and SCD1 protein expression in mouse
kidney was analyzed by western blotting. TO901317 induced a more significant upregulation of both of these proteins in kidney, which was
also confirmed by immunofluorescence. (d, e) The expressions of ABCA1 and SCD1 were also increased in mouse ileum. Protein increase of
SCD1 was not observed with DMHCA. Values represent means±s.e.m., at least n¼ 6 mice per group. ChREBP, carbohydrate-responsive-
element-binding protein; DMHCA, N,N-dimethyl-3b-hydroxy-cholenamide; LPK, liver pyruvate kinase; LXR, liver X receptor;
NS, nonsignificant; SCD1, stearoyl-CoA desaturase 1; SREBP1c, sterol-regulatory-element-binding protein 1c.
Kidney International (2011) 80, 535–544 537
YA Caldas et al.: LXR inhibits the expression of NaPi transporters o r ig ina l a r t i c l e
we found that DMHCA did not alter renal Na-glucose SGLT-2
protein levels, whereas TO901317 caused a decrease of
SGLT-2 protein abundance (Supplementary Figure C online).
Measurements of the mRNA abundance of these
transporters in parallel samples of the kidney cortex by
real-time quantitative PCR indicate that these ligands
decrease the mRNA abundance of NaPi-2a and NaPi-2c but
not Pit-2 (Figure 5b).
Treatment with DMHCA or TO901317 also caused a
significant decrease in ileum BBM NaPi-2b protein abun-
dance, with no significant effects on Pit-1 protein abundance
(Figure 6a). The effect of these ligands on the intestinal NaPi-
2b transporter abundance was independent of the alterations
in the protein abundance of the PDZ-domain-interacting
proteins, namely, NHERF-1 and PDZK-1 (Figure 6c).
In addition, we found no effects of these LXR agonists on
the intestinal Na-glucose SGLT1 transporter protein levels
(Supplementary Figure B online).
The effect of DMHCA or TO901317 on NaPi-2b protein
abundance was associated with a parallel decrease in NaPi-2b
mRNA; 75% after treatment with TO901317 and 50% with
DMHCA (Figure 6b).
DMHCA or TO901317 causes decreases in NaPi cotransport
activity and NaPi-4 protein abundance in opossum kidney
(OK) cells in culture
To determine whether DMHCA or TO901317 has direct
modulatory effects on NaPi cotransport activity, independent
of systemic metabolic and hormonal factors, we studied their
effects in OK cells. OK cells are a well-established model of
the renal proximal tubule, which expresses the endogenous
type IIa NaPi cotransporter, also known as NaPi-4. Treatment
of OK cells with DMHCA induced translocation of LXR to
the nucleus (Figure 7a). This effect was also observed with
TO901317 compound (data not shown). Both LXR agonists
200
Ileum BBM NaPi uptake
32P uptake
200
150
Pi
 u
pa
tk
e
(nm
ol/
mg
 pr
ote
in 
in 
30
 s)
100
50
0
NaCl Choline
NaCl Choline
20.8
147.5
150
100
Pi
 u
pa
tk
e
(nm
ol/
mg
 pr
ote
in 
in 
30
 s)
50
0
Control
1200
1000
*
*
800
600
Pi
 u
pa
tk
e
(nm
ol/
mg
 pr
ote
in 
in 
10
 s)
400
200
0
Kidney BBM NaPi uptake
32P uptake
1000 812
38.3
900
800
700
80
60
40
20
0
Pi
 u
pa
tk
e
(nm
ol/
mg
 pr
ote
in 
in 
10
 s)
DMHCA
*
*
TO901317
Control DMHCA TO901317
15
Serum Pi
10
Control
* **
****
0
5
DMHCA TO901317 Control DMHCA TO901317 Control DMHCA TO901317
20
Urine Pi/creatinine
15
10
5
0
15
10 NS NS
Serum calcium
5
0
m
g/
dl
Pi
 (m
g) 
cre
ati
nin
e,
24
 h
 (m
g)
m
g/
dl
Figure 3 |Treatment with DMHCA or TO901317 decreases blood phosphate concentration, increases urine phosphate excretion in
mouse, and does not change serum calcium concentration. (a) Treatment with TO901317 caused a 20% decrease in serum phosphate
concentration, with a smaller reduction of 14% after treatment with DMHCA. (b) Approximately a 30% increase in urine phosphate excretion
with either compound. (c) No changes in the serum calcium concentration were observed with either compound. At least n¼ 10 mice
per group. DMHCA, N,N-dimethyl-3b-hydroxy-cholenamide; NS, nonsignificant; Pi, inorganic phosphate.
Figure 2 |Treatment with DMHCA or TO901317 reduces
Naþ -dependent phosphate uptake in mouse ileum and
kidney BBM. (a) Sodium-dependent 32P uptake was reduced in
ileum BBM in DMHCA- or TO901317-treated mice. (b) Sodium-
dependent 32P was also reduced in kidney BBM in DMHCA- or
TO901317-treated mice. Small panels in the upper right show
sodium-independent uptake, measured in presence of Cl-choline,
compared with the total phosphate uptake (NaCl). These values
represent the average of two different experiments with at
least n¼ 10 per group. BBM, brush border membrane; DMHCA,
N,N-dimethyl-3b-hydroxy-cholenamide; NaPi, sodium–phosphate;
Pi, inorganic phosphate.
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caused a dose-dependent decrease in OK cell NaPi cotran-
sport activity (Figure 7b), measured by whole-confluent cells
32P uptake. Western blot of apical membranes isolated from
OK cells and immunofluorescence studies indicate that these
agonists caused parallel decreases in the apical membrane
NaPi-4 protein abundance (Figure 7c, d and Supplementary
Figure D online).
DISCUSSION
Hyperphosphatemia is a major risk factor for cardiovascular
disease. Any interventions that decrease serum Pi concentra-
tion and possibly prevent the cardiovascular consequences of
hyperphosphatemia are welcomed. In this study, we show
that TO901317 and DMHCA, two LXR-activating ligands,
which have been previously described and shown to prevent
atherosclerosis in ApoE-knockout mice,22 also causes a
significant decrease in serum Pi concentration by inhibiting
the activity of the renal and intestinal NaPi transporters.
The effects of TO901317 or DMHCA in decreasing renal
proximal tubular BBM NaPi cotransport activity are reflected
by an increase in the urinary Pi excretion and significant
decreases in the abundance of NaPi-2a, NaPi-2c, and Pit-2.
Although the decreases in NaPi-2a and NaPi-2c protein
abundance may be mediated by the transcriptional mechan-
isms, the decrease in Pit-2 protein abundance seems to be
independent of Pit-2 transcriptional regulation. These results
are associated with a significant increase of the FGF23 serum
levels after treatment with LXR agonist. FGF23 is a well-
known phosphaturic hormone38 capable of downregulating
the expression of the renal NaPi transporters. In addition,
it is also important to mention that the protein levels of the
Na-glucose transporters SGLT2 in kidney BBM are also
reduced after treatment with TO901317, with no significant
effects with DMHCA.
It is now quite well established that NaPi–PDZ-type
(PSD-95, discs-large, and ZO-1) protein interactions are
important for the regulation of NaPi-2a and NaPi-2c protein
expression in the proximal tubular apical BBM.39–41 Our
studies indicate that the effects of these LXR agonists
on NaPi-2a, NaPi-2c, and NaPi-2b protein abundance are
independent of alterations on BBM expression of the PDZ
proteins, NHERF-1 or PDZK-1. However, LXR-induced
modifications in NHERF-1 or PDZK-1–NaPi interactions
cannot be ruled out.
DMHCA and TO901317 also have marked effects in
inhibiting intestinal BBM NaPi cotransport activity. This
inhibition occurs via a major decrease in the BBM protein
abundance of the major intestinal NaPi transporter NaPi-2b.
There is also a parallel decrease in NaPi-2b mRNA
abundance, which indicates that DMHCA and TO901317
may downregulate NaPi-2b via transcriptional mechanisms.
To determine whether LXR activation has also direct
effects in modulating NaPi cotransport activity, we have
performed parallel studies in OK cells, a well-established
model of the renal proximal tubule.39,42 We found that both
of the LXR agonists cause a dose-dependent decrease in OK
cells NaPi cotransport activity by decreasing the apical BBM
abundance of the OK cell type II NaPi cotransporter NaPi-4
protein. Additional studies indicate that DMHCA as well as
TO901317 induce increased nuclear expression of LXR
protein, further supporting that these drugs are LXR-
activating ligands; this is correlated with the upregulation
of LXR target genes, including ABCA1 (data not shown),
after treatment of the OK cells with this agonist.
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Figure 4 | Effects of DMHCA and TO901317 on mouse serum
FGF23 and serum PTH. (a) Treatment with TO901317 caused a
64% increase in serum FGF23 concentration, with a smaller
increase of 46% after treatment with DMHCA. (b) Changes on the
serum PTH levels were determined to be not significant
for both compounds. At least n¼ 10 mice per group.
DMHCA, N,N-dimethyl-3b-hydroxy-cholenamide; FGF23, fibroblast
growth factor 23; NS, nonsignificant; PTH, parathyroid hormone.
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Our study demonstrates that LXR has a novel role in
inhibiting renal and intestinal NaPi transporters and
decreasing serum Pi concentration through multiple me-
chanisms, including phosphatonin modulation and direct
control of Pi transporter abundance in epithelia. This effect
of LXR, along with its well-established effects in mediating
reverse cholesterol transport, inhibiting inflammatory
cytokines, and preventing atherosclerosis, establishes it as a
major target for the prevention of hyperphosphatemia and
the associated cardiovascular complications.
MATERIALS AND METHODS
Animals and diets
Male C57Bl/6 mice were purchased from Jackson Laboratory (Bar
Harbor, ME) and maintained in a clean environment on a regular
12-h light–12-h dark cycle. Before the initiation of the corresponding
diets, mice were kept on a standard laboratory chow diet (Harland
Teklad 2019 chow diet) with 0.9% of Ca and 0.7% of Pi. Male
C57Bl/6 mice were fed chow diet containing (a) no ligands, or
(b) DMHCA (80mg/kg body weight/day), or (c) T0901317 (35mg/
kg body weight/day) for 15 days. Diets were supplemented with the
respective LXR ligand at a level sufficient to provide the appropriate
mg/kg food dose on consumption of a 5 g diet by a 25 g mouse/day.
Body weight and food intake were monitored regularly. We studied
n¼ 24 mice in each treatment group: 12 mice for renal and intestinal
BBM isolation and 12 mice for renal and intestinal RNA isolation.
On the 14th day of the treatment, the mice were placed in metabolic
balance cages for urine collection. Animal experiments were
approved by the Institutional Animal Care and Research Advisory
Committee of the University of Colorado at Denver.
Cell culture
OK proximal tubule cells were grown in DMEM-F-12 (Invitrogen,
Carlsbad, CA) supplemented with 10% fetal bovine serum, 50U/ml
penicillin, and 50 mg/ml streptomycin. For experimental work, cells
were seeded on porous membrane inserts (Corning, Lowell, MA).
After confluency, cells were placed in DMEM-F-12 supplemented
with 0.2% fetal bovine serum and penicillin/streptomycin to get
them quiescent for 24–48 h before treatment. Cells were treated with
different concentration of LXR agonist, either DMHCA or
TO901317 (stocks were resuspended in dimethyl sulfoxide). Work-
ing solutions of these agonists were prepared in DMEM-F-12
supplemented with 0.2% fetal bovine serum and penicillin/
streptomycin. Cells were treated with 1:1000 dilution of dimethyl
sulfoxide (control) or DMHCA or TO901317 for 24 h.
Materials and antibodies
All chemicals were obtained from Sigma (Saint Louis, MI), except
when noted. A polyclonal rabbit anti-NaPi-IIa antibody was
generated by Affinity Bio Reagents (Golden, CO) and used at
1:5,000 for western blotting.13 A rabbit anti-NaPi-IIc antibody was
custom-made by Davids Biotechnologie (Regensburg, Germany), as
previously described,13 and was used at 1:1000 for western blotting.
The polyclonal rabbit anti-NaPi-2b, anti-PiT1, and anti-PiT2
Figure 5 | Effects of DMHCA or TO901317 on renal BBM NaPi
transporter protein abundance and NaPi transporter mRNA
abundance. (a) Mouse kidney brush border membrane (BBM)
vesicles were isolated after treatment with DMHCA or TO901317.
A significant decrease in protein abundance was observed in all
three NaPi transporters: 57% for NaPi-2a, 40% for NaPi-2c, and
30% for PiT-2. (b) NaPi transporter mRNA abundance was
measured by quantitative PCR and normalized against cyclophilin A.
Decreases in NaPi-2a and NaPi-2c mRNA levels were observed
with either DMHCA or TO901317. (c) NHERF1 and PDZK1 protein
levels were not affected by these LXR agonists. At least n¼ 6-8
mice per group. BBM, brush border membrane; DMHCA,
N,N-dimethyl-3b-hydroxy-cholenamide; NHERF1, Na/H exchange
regulatory factor-1; NaPi, sodium-phosphate; NS, nonsignificant.
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antibodies were also custom generated by Davids Biotechnologie
(Regensburg, Germany) as described before,14 and was used
at 1:1,000 dilution for western blotting. The goat anti-LXRa/b
was purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
The rabbit anti-ABCA1 was purchased from Novus Biologicals
(Littleton, CO), and the rabbit anti-stearoyl-CoA desaturase 1 was
purchased from Cell Signaling Technology (Danvers, MA). The
rabbit anti-Na/H exchange regulatory factor-1 antibody was
purchased from Sigma. The rabbit anti-PDZK1 was a kindly gift
from Dr David Silver (Columbia University).
BBM vesicle isolation
Mice were anesthetized via an intraperitoneal injection of 50mg/kg
pentobarbital sodium (Pentothal, Abbott Laboratories, Abbott Park,
IL). After clamping of the renal vessels, blood was drawn for
biochemical analysis, the kidneys and the ileum were removed, and
the ileum mucosa was scraped for BBM isolation.
Kidney slices from two mice were combined in 7.5ml isolation
buffer consisting of 15mmol/l Tris HCl (pH 7.4), 300mmol/l
mannitol, 5mmol/l ethylene glycol tetraacetic acid, and 1 Roche
Complete inhibitor tablet per 250ml buffer. The kidney slices were
homogenized using a Potter-Elvejham homogenizer with 8–10 rapid
strokes and transferred to a chilled capable tube. Kidney residues
remaining on the homogenizer were rinsed off with 10ml water that
was then added to the kidney homogenate. BBM was prepared by a
double Mg2þ precipitation. For the first Mg2þ precipitation, MgCl2
was added to the homogenate (final concentration of 15mmol/l),
and the homogenate was shaken every 5min on ice for 20min
before centrifugation at 2500 g for 15min. The supernatant was
subjected to a second Mg2þ precipitation; and from the resulting
supernatant, the BBM was recovered by centrifugation at 38,000 g
for 40min. The BBM was resuspended, and its protein content
quantified.
Ileum BBM was similarly isolated by double Mg2þ precipitation
as describe above. BBM of the OK cells was isolated by Mg2þ
precipitation. Briefly, OKP cells were grown to confluence in
100mm dishes. At 24 h before the experiment, the cells were placed
in DMEM medium containing 0.2% fetal bovine serum to
synchronize them. Cells were incubated with control media
(1:1000 dimethyl sulfoxide) or DMHCA or TO901317 for 24 h.
After treatment, the cells were washed in ice cold PBS and scraped
into isolation buffer (15mmol/l Tris (pH7.4), 300mmol/l mannitol,
5mmol/l ethylene glycol tetraacetic acid, and one Mini-Complete
tablet (Roche)) on ice. The cells were then homogenized by
aspirating 30 times through a 23-gauge needle. MgCl2 was added to
a final concentration of 15mmol/l, and the homogenate was shaken
on ice for 20min. The homogenate was centrifuged at 2500 g at
4 C for 15min. The supernatant was removed and spun at
60,000 g for 40min. The final pellet was resuspended in isolation
buffer.
Pi transport assays
Phosphate transport from kidney or ileum was measured
by rapid filtration of radioactive 32Pi uptake in freshly isolated
BBM vesicles.43 The BBM and the uptake solution were incubated
for 10 s at 251C for kidney and 30 s at 371C for ileum. Phosphate
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Figure 6 | Effects of DMHCA or TO901317 on intestinal BBM
NaPi transporter protein abundance and NaPi transporter
mRNA abundance. (a) Mouse ileum brush border membrane
(BBM) vesicles were isolated after treatment with DMHCA or
TO901317. There was a significant 61% decrease in the protein
abundance of the major intestinal NaPi transporter NaPi-2b with
TO901317 treatment, and a 52% after treatment with DMHCA,
while there were no significant changes in type III NaPi
transporter PiT1 protein expression. (b) NaPi2b mRNA abundance
was reduced by 50% after treatment with DMHCA, and by 75%
with TO901317. (c) NHERF1 and PDZK1 protein levels were not
significantly affected by DMHCA or TO901317. At least n¼ 6 mice
per group. BBM, brush border membrane; DMHCA, N,N-dimethyl-
3b-hydroxy-cholenamide; NHERF1, Na/H exchange regulatory
factor-1; NaPi, sodium-phosphate; NS, nonsignificant.
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transport in OK cells was measured by radioactive. 32Pi uptake in
treated confluent cells for 6min at 251C, as described.14,40,44
Urine and blood analysis
Blood samples were collected in heparin-containing tubes during
sacrifice. The 24 h and spot urine was collected in animals treated for
2 weeks. Plasma obtained after centrifugation and urine samples
were analyzed for phosphate (Pi) concentrations by using the
commercial kit Stanbio Liqui-UV (Stanbio; Boerne, TX). Creatinine
concentration in urine was determined using QuantiChrom
Creatinine Assay (BioAssay Systems; Hayward, CA). FGF-23
(C-Term) and intact parathyroid hormone were determined with
specific ELISA kits from Immunotopics (San Clemente, CA).
n¼ 10–12 animals per group was used in these assays.
Western blotting
BBM proteins (20 or 30mg) were separated by 10% SDS-polyacryla-
mide gel electrophoresis, and transferred onto nitrocellulose mem-
branes. Membranes were blocked with 5% milk in PBS Tween
20 before incubation with primary antibodies diluted in PBTS
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Figure 7 | Treatment of opossum kidney (OK) cells with LXR agonists DMHCA or TO901317 induces activation of endogenous LXR,
decrease in the phosphate uptake in a dose-dependent manner, and decrease in the expression of the endogenous NaPi
transporter (NaPi4). (a) Activation and translocation of the endogenous LXR nuclear receptor is shown by immunofluorescence after
incubation of the OK cells with DMHCA. Notice the increased red signal inside the nucleus in the treated cells. (b) Correlation between
concentration of the LXR agonist and reduction of the whole cells 32P uptake was observed for both compounds. (c) Reduced expression of
the endogenous NaPi4 phosphate transporter is observed by immunofluorescence in the apical membrane of OK cells. Notice the decrease
in the red signal, and (d) this is confirmed by western blot in isolated OK cell BBM. At least n¼ 3 per group. BBM, brush border membrane;
DMHCA, N,N-dimethyl-3b-hydroxy-cholenamide; NaPi, sodium-phosphate; NS, nonsignificant; OK, opossum kidney; Pi, inorganic phosphate;
SCD1, stearoyl-CoA desaturase 1.
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overnight at 4 1C. After washes with phosphate buffered saline
and Tween 20, membranes were incubated with Licor-conjugated
(LI-COR, Lincoln, NE) donkey secondary antibodies diluted 1:5,000
for 1 h. Membranes were scanned using Licor system. Densitometry
data are presented as average±s.d.
RNA extraction and real-time quantitative PCR
Total RNA was isolated from kidney cortex and ileum using
the Qiagen RNeasy Mini Kit, and complementary DNA was
synthesized using reverse transcription reagents from Bio-Rad
(Hercules, CA). The mRNA level was quantified using a Bio-Rad
iCyCler real-time PCR machine. Cyclophilin A was used as an
internal control, and the amount of RNA was calculated by the
comparative threshold cycle method as recommended by the
manufacturer. All of the data were calculated from duplicate
reactions of three different experiments.
Confocal microscopy
Cells were washed with PBS before blocking for 30min with 5%
goat serum and permeabilized with 0.1% saponin in PBS. Cells were
then incubated overnight at 41C with primary antibodies. After
washing with saponin solution, sections were incubated with
secondary fluorescent goat antibodies for 1 h. After washing three
times, the cells were mounted in Vectashield (Vector Labs,
Burlingame, CA). Confocal images were acquired on a Zeiss 510
NLO-META LSM laser scanning confocal microscope (Carl Zeiss,
Thornwood, NY), and the Olympus Fluoview 1000 confocal
microscope (Olympus, Center Valley, PA).
Statistical analysis
Data are expressed as means±s.d., *Po0.05, **Po0.005, and
***Po0.001. Data were analyzed for statistical significance by
unpaired Student’s t-test or one-way analysis of variance.
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SUPPLEMENTARY MATERIAL
Figure A. Treatment with DMHCA or TO901317 compound induced a
small significant decrease in the urine pH compared to control
samples.
Figure B. Protein abundance by western blotting of the renal
Na-glucose transporter SGLT2 in BBM showed a significant reduction
after treatment with TO901317 compound. No significant change
was observed with DMHCA.
Figure C. Protein abundance by western blotting of the Na-glucose
transporter SGLT1 in intestinal BBM shows no significant changes
after treatment with neither compound.
Figure D. Western blotting of NaPi4 in OK cells BBM showing
down-regulation after treatment with either LXR agonist.
Supplementary material is linked to the online version of the paper at
http://www.nature.com/ki
REFERENCES
1. Tonelli M, Pannu N, Manns B. Oral phosphate binders in patients with
kidney failure. N Engl J Med 2010; 362: 1312–1324.
2. Foley RN. Phosphate levels and cardiovascular disease in the general
population. Clin J Am Soc Nephrol 2009; 4: 1136–1139.
3. Foley RN, Collins AJ, Herzog CA et al. Serum phosphorus levels associate
with coronary atherosclerosis in young adults. J Am Soc Nephrol 2009; 20:
397–404.
4. Ix JH, De Boer IH, Peralta CA et al. Serum phosphorus concentrations and
arterial stiffness among individuals with normal kidney function to
moderate kidney disease in MESA. Clin J Am Soc Nephrol 2009; 4: 609–615.
5. Chiu YW, Adler SG, Budoff MJ et al. Coronary artery calcification and mortality
in diabetic patients with proteinuria. Kidney Int 2010; 77: 1107–1114.
6. Villa-Bellosta R, Bogaert YE, Levi M et al. Characterization of phosphate
transport in rat vascular smooth muscle cells: implications for vascular
calcification. Arterioscler Thromb Vasc Biol 2007; 27: 1030–1036.
7. Brandenburg VM, Jahnen-Dechent W, Ketteler M. Sevelamer and the
bone-vascular axis in chronic kidney disease: bone turnover,
inflammation, and calcification regulation. Kidney Int Suppl 2009; 114:
S26–S33.
8. Miyazaki-Anzai S, Levi M, Kratzer A et al. Farnesoid X receptor activation
prevents the development of vascular calcification in ApoE-/- mice with
chronic kidney disease. Circ Res 2010; 106: 1807–1817.
9. Virkki LV, Biber J, Murer H et al. Phosphate transporters: a tale of two
solute carrier families. Am J Physiol Renal Physiol 2007; 293: F643–F654.
10. Forster IC, Hernando N, Biber J et al. Proximal tubular handling of
phosphate: a molecular perspective. Kidney Int 2006; 70: 1548–1559.
11. Kiela PR, Ghishan FK. Recent advances in the renal-skeletal-gut axis
that controls phosphate homeostasis. Lab Invest 2009; 89: 7–14.
12. Villa-Bellosta R, Sorribas V. Compensatory regulation of the sodium/
phosphate cotransporters NaPi-IIc (SCL34A3) and Pit-2 (SLC20A2)
during Pi deprivation and acidosis. Pflugers Arch 2010; 459: 499–508.
13. Breusegem SY, Takahashi H, Giral-Arnal H et al. Differential regulation
of the renal sodium-phosphate cotransporters NaPi-IIa, NaPi-IIc, and PiT-2
in dietary potassium deficiency. Am J Physiol Renal Physiol 2009; 297:
F350–F361.
14. Giral H, Caldas Y, Sutherland E et al. Regulation of the Rat Intestinal
Na-dependent Phosphate Transporters by Dietary Phosphate. Am J
Physiol Renal Physiol 2009; 297: F1466–F1475.
15. Sabbagh Y, O’Brien SP, Song W et al. Intestinal npt2b plays a major role
in phosphate absorption and homeostasis. J Am Soc Nephrol 2009; 20:
2348–2358.
16. Hansen MK, Connolly TM. Nuclear receptors as drug targets in obesity,
dyslipidemia and atherosclerosis. Curr Opin Investig Drugs 2008; 9:
247–255.
17. Bensinger SJ, Tontonoz P. Integration of metabolism and inflammation
by lipid-activated nuclear receptors. Nature 2008; 454: 470–477.
18. Bensinger SJ, Bradley MN, Joseph SB et al. LXR signaling couples sterol
metabolism to proliferation in the acquired immune response. Cell 2008;
134: 97–111.
19. Joseph SB, McKilligin E, Pei L et al. Synthetic LXR ligand inhibits the
development of atherosclerosis in mice. Proc Natl Acad Sci USA 2002; 99:
7604–7609.
20. Terasaka N, Hiroshima A, Koieyama T et al. T-0901317, a synthetic liver
X receptor ligand, inhibits development of atherosclerosis in LDL
receptor-deficient mice. FEBS Lett 2003; 536: 6–11.
21. Kim GH, Park K, Yeom SY et al. Characterization of ASC-2 as an
antiatherogenic transcriptional coactivator of liver X receptors in
macrophages. Mol Endocrinol 2009; 23: 966–974.
22. Kratzer A, Buchebner M, Pfeifer T et al. Synthetic LXR agonist attenuates
plaque formation in apoE-/- mice without inducing liver steatosis and
hypertriglyceridemia. J Lipid Res 2009; 50: 312–326.
23. Hong C, Tontonoz P. Coordination of inflammation and metabolism by
PPAR and LXR nuclear receptors. Curr Opin Genet Dev 2008; 18: 461–467.
24. Tontonoz P, Mangelsdorf DJ. Liver X receptor signaling pathways in
cardiovascular disease. Mol Endocrinol 2003; 17: 985–993.
25. Wang XX, Jiang T, Levi M. Nuclear hormone receptors in diabetic
nephropathy. Nat Rev Nephrol 2010; 6: 342–351.
26. Rizzo G, Fiorucci S. PPARs and other nuclear receptors in inflammation.
Curr Opin Pharmacol 2006; 6: 421–427.
27. Peet DJ, Turley SD, Ma W et al. Cholesterol and bile acid metabolism
are impaired in mice lacking the nuclear oxysterol receptor LXR alpha.
Cell 1998; 93: 693–704.
28. Janowski BA, Willy PJ, Devi TR et al. An oxysterol signalling pathway
mediated by the nuclear receptor LXR alpha. Nature 1996; 383: 728–731.
29. Knight BL, Patel DD, Humphreys SM et al. Inhibition of cholesterol
absorption associated with a PPAR alpha-dependent increase in ABC
binding cassette transporter A1 in mice. J Lipid Res 2003; 44: 2049–2058.
30. Wojcicka G, Jamroz-Wisniewska A, Horoszewicz K et al. Liver X receptors
(LXRs). Part I: structure, function, regulation of activity, and role in lipid
metabolism. Postepy Hig Med Dosw (Online) 2007; 61: 736–759.
Kidney International (2011) 80, 535–544 543
YA Caldas et al.: LXR inhibits the expression of NaPi transporters o r ig ina l a r t i c l e
31. Kalaany NY, Mangelsdorf DJ. LXRS and FXR: the yin and yang of
cholesterol and fat metabolism. Annu Rev Physiol 2006; 68: 159–191.
32. Quinet EM, Savio DA, Halpern AR et al. Gene-selective modulation by a
synthetic oxysterol ligand of the liver X receptor. J Lipid Res 2004; 45:
1929–1942.
33. Morello F, de Boer RA, Steffensen KR et al. Liver X receptors alpha and
beta regulate renin expression in vivo. J Clin Invest 2005; 115: 1913–1922.
34. Zhang Y, Mangelsdorf DJ. LuXuRies of lipid homeostasis: the unity of
nuclear hormone receptors, transcription regulation, and cholesterol
sensing. Mol Interv 2002; 2: 78–87.
35. Levy E, Spahis S, Sinnett D et al. Intestinal cholesterol transport proteins:
an update and beyond. Curr Opin Lipidol 2007; 18: 310–318.
36. Kaneko E, Matsuda M, Yamada Y et al. Induction of intestinal ATP-binding
cassette transporters by a phytosterol-derived liver X receptor agonist.
J Biol Chem 2003; 278: 36091–36098.
37. Zhang Y, Zhang X, Chen L et al. Liver X receptor agonist TO-901317
upregulates SCD1 expression in renal proximal straight tubule.
Am J Physiol Renal Physiol 2006; 290: F1065–F1073.
38. Komaba H, Fukagawa M. FGF23-parathyroid interaction: implications in
chronic kidney disease. Kidney Int 2010; 77: 292–298.
39. Hernando N, Deliot N, Gisler SM et al. PDZ-domain interactions and apical
expression of type IIa Na/P(i) cotransporters. Proc Natl Acad Sci USA 2002;
99: 11957–11962.
40. Lanaspa MA, Giral H, Breusegem SY et al. Interaction of MAP17
with NHERF3/4 induces translocation of the renal Na/Pi IIa
transporter to the trans-Golgi. Am J Physiol Renal Physiol 2007; 292:
F230–F242.
41. Villa-Bellosta R, Barac-Nieto M, Breusegem SY et al. Interactions of the
growth-related, type IIc renal sodium/phosphate cotransporter with PDZ
proteins. Kidney Int 2008; 73: 456–464.
42. Sorribas V, Markovich D, Hayes G et al. Cloning of a Na/Pi
cotransporter from opossum kidney cells. J Biol Chem 1994; 269:
6615–6621.
43. Sorribas V, Lotscher M, Loffing J et al. Cellular mechanisms of the
age-related decrease in renal phosphate reabsorption. Kidney Int 1996;
50: 855–863.
44. Breusegem SY, Halaihel N, Inoue M et al. Acute and chronic changes
in cholesterol modulate Na-Pi cotransport activity in OK cells.
Am J Physiol Renal Physiol 2005; 289: F154–F165.
544 Kidney International (2011) 80, 535–544
or ig ina l a r t i c l e YA Caldas et al.: LXR inhibits the expression of NaPi transporters
